- About us
- About Vaccines
- Media centre
- Become a member
Vaccines Europe represents all the major vaccine companies operating in Europe which undertake 79% of their global production and more than 50% of their global research projects in the region.
Today is World Hepatitis Day. The World Health Organisation (WHO) estimates that every year viral hepatitis kills 1.4 million men and women on average, with many more becoming newly infected. This is why, the theme of this year’s campaign is Prevent Hepatitis. Achieving this goal means not only building appropriate awareness among the general public and healthcare staff on how different types of hepatitis infection can be prevented, but also on how to improve access to and delivery of the core services that improve vaccinations against it, blood and injection safety, and reduced harm. With better prevention, 4000 lives can be saved per day.
Join the debate on Twitter using the hashtag #PreventHepatitis
And visit www.worldhepatitisday.org
The European Medicines Agency has today adopted a positive scientific opinion for the world’s first malaria vaccine, submitted for approval by vaccine manufacturer GSK. The vaccine was developed in partnership with the PATH Malaria Vaccine Initiative, and is the first candidate vaccine for the prevention of malaria to reach this milestone. The vaccine has been designed to prevent malaria caused by the most prevalent parasite in sub-Saharan Africa. Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. In 2013, malaria caused an estimated 584 000 deaths, mostly among African children. Read more…
Vaccines Europe welcomes the new financing tool dedicated specifically to R&D in infectious diseases that has been launched by the European Commission and the European Investment Bank.
This new instrument, InnovFin Infectious Diseases, was established within the InnovFin – EU Finance for Innovators family of instruments and will provide loans to high-risk projects in the area of infectious disease R&D and reinvigorate and attract co-investment from other investors by incentivising R&D activities for an uncertain market. It can be accessed by small, medium and large companies, research infrastructures, universities, non-profit organisations, and Special Purpose Vehicles (SPV) established and operating in one or several of the EU Member States and Associated Countries. Read more…